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Abstract
Purpose To define the role of focal laser ablation (FLA) as clinical treatment of prostate cancer (PCa) using the Delphi 
consensus method.
Methods A panel of international experts in the field of focal therapy (FT) in PCa conducted a collaborative consensus 
project using the Delphi method. Experts were invited to online questionnaires focusing on patient selection and treatment 
of PCa with FLA during four subsequent rounds. After each round, outcomes were displayed, and questionnaires were 
modified based on the comments provided by panelists. Results were finalized and discussed during face-to-face meetings.
Results Thirty-seven experts agreed to participate, and consensus was achieved on 39/43 topics. Clinically significant PCa 
(csPCa) was defined as any volume Grade Group 2 [Gleason score (GS) 3+4]. Focal therapy was specified as treatment of 
all csPCa and can be considered primary treatment as an alternative to radical treatment in carefully selected patients. In 
patients with intermediate-risk PCa (GS 3+4) as well as patients with MRI-visible and biopsy-confirmed local recurrence, 
FLA is optimal for targeted ablation of a specific magnetic resonance imaging (MRI)-visible focus. However, FLA should 
not be applied to candidates for active surveillance and close follow-up is required. Suitability for FLA is based on tumor 
volume, location to vital structures, GS, MRI-visibility, and biopsy confirmation.
Conclusion Focal laser ablation is a promising technique for treatment of clinically localized PCa and should ideally be 
performed within approved clinical trials. So far, only few studies have reported on FLA and further validation with longer 
follow-up is mandatory before widespread clinical implementation is justified.
Keywords Laser focal therapy · Focal laser ablation · Prostate cancer · Consensus · Delphi
Introduction
The incidence of prostate cancer (PCa) is increasing with 
approximately 164,000 newly diagnosed cases in the US in 
2018 [1]. Whole-gland therapy, i.e., radical prostatectomy 
(RP), external radiation therapy (RT), and brachytherapy are 
common treatment forms for PCa, providing excellent long-
term efficacy but also come with treatment-related compli-
cations and side effects [2]. Studies reported urinary incon-
tinence (13.4% and 4.4%, respectively), erectile function 
(EF) (75.7% and 71.9%, respectively) and bowel urgency 
(16.3% and 31.3%, respectively) within 5 years after RP or 
RT, resulting in a measurable decrease in quality of life [3]. 
Minimally invasive techniques are used for organ-confined 
PCa and are a novel strategy for targeted treatment, while 
preserving healthy tissue and subsequently reduce treatment-
related morbidity [4]. Currently, a wide variety of energy 
sources seem to be capable for FT, i.e., focal laser abla-
tion (FLA) cryosurgery, high intensity-focused ultrasound 
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(HIFU), radiofrequency, microwave, and irreversible elec-
troporation/nanoknife (IRE) [5–7].
Accurate imaging of PCa in conjunction with the asso-
ciated anatomy is crucial for an effective and successful 
treatment. Multiparametric magnetic resonance imaging 
(mpMRI) is preferred for cancer localization and treatment 
planning over other imaging modalities due to its excellent 
soft-tissue contrast and multi-planar, anatomical imaging. 
It is also suitable for image guidance during treatment and 
long-term follow-up after FT [8]. During image-guided 
treatments, MRI-based temperature-mapping provides 
real-time feedback of the thermal distribution in the pros-
tate and thereby increasing both precision and control. Also, 
MRI–transrectal ultrasound (TRUS) fusion appears to be 
safe and feasible for FLA guidance and monitoring [9].
The clinical use of FLA for localized PCa is not estab-
lished yet and further evaluation is needed before it can 
be recognized as FT. The FLA thermal ablation technique 
is applied with a laser fiber and by raising the tempera-
ture > 60 °C, it results in direct focused cell death. Only few 
studies with small sample sizes and maximum follow-up 
of 1 year reported on the clinical use of FLA and, there-
fore, are lacking in long-term evidence [10–13]. However, 
they provide patient benefits supporting image-guided FLA 
as appealing technique and feasible and safe for minimal-
invasive treatment, in men with low- and intermediate-risk 
PCa [Gleason score (GS) ≤ 3+4] who are eligible for both 
active surveillance (AS) and radical treatment. Targeted 
biopsies from the ablation zone showed no recurrence within 
3 months after FLA in 96%. Systematic biopsies after 1 year 
showed a residual GS ≥ 3+3 in 11%. As a surrogate marker 
for efficacy, the mean prostate-specific antigen (PSA) has 
decreased by 40% following FLA [14, 15]. The aim of this 
international collaborative consensus project was to define 
the role of image-guided FLA as potential clinical treatment 
in patients with clinically localized PCa using the Delphi 
consensus method among experts in the field [16].
Method
To achieve consensus among a panel of experts in the field, 
the Delphi method was used [16]. According to this method, 
online questionnaires were presented to participants during 
several rounds. The goal was to obtain consensus by reduc-
ing the range of answers after each round.
A systematic literature search was conducted using the 
PubMed database on “prostate” (and synonyms), “can-
cer” (and synonyms), “focal laser ablation” (and syno-
nyms), “magnetic resonance imaging” (and synonyms), 
and “focal therapy” (and synonyms), with filters: Full text, 
to 2016/07/01, Humans, English. This search yielded 20 
articles (Fig. 1), while only 10 articles were eligible for 
controversial topic selection.
Panelists were selected based on the literature search 
and peer recommendations. The survey was conducted and 
presented in four subsequent rounds between 28 November 
2016 and 14 June 2017, using online questionnaire software 
(www.surve ymonk ey.com; San Mateo, USA). Question-
naires were modified after each round based on responses 
and feedback. A (statistical) summary of the previous rounds 
was provided allowing the experts to re-evaluate their opin-
ion. The level of agreement to achieve consensus was set at 
70% and descriptive statistics were used to determine the 
response rate of each topic. The selected topics from the 
literature search were demographics, patient characteristics, 
role of biopsy/imaging in FLA, tumor size, outcome, and 
genomics. Online Resource 1 displays an overview of the 
questionnaires.
During a face-to-face meeting at the American Urological 
Association Annual Meeting on 13 May 2017, the results of 
the first three rounds were presented and inconclusive topics 
were discussed. Remaining questions were reworded and 
presented in a fourth round. Final results of the project were 
discussed during a meeting at the Radiological Society of 
North America (RSNA) on 26 November 2017.
Results
Seventy-five international experts were invited, and 37 
experts agreed to participate. Response rates were 100% 
(37/37), 70% (26/37), 68% (25/37), and 65% (24/37) for 
rounds 1–4, respectively. Fifty-one percent (19/37) were 
urologists, 38% (14/37) (interventional) radiologists, 3% 
(1/37) radiation oncologist, 3% (1/37) researcher, 3% (1/37) 
technical physician, and 3% (1/37) engineer. Seventy-eight 
MRI = Magnec resonance imaging; mpMRI = mulparametric MRI
(prostate[tiab] OR prostatic[tiab] OR prostatae[tiab]) AND (“Neoplasms”[Mesh] OR
carcinoma[tiab] OR cancer*[tiab] OR neoplasm*[tiab] OR malignan*[tiab] OR
adenocarcinoma[tiab] OR adenocarcinom[tiab] OR tumor*[tiab] OR tumour*[tiab]
OR cancers[tiab]) AND (“Laser Therapy”[Mesh] OR Laser ablation[tiab] OR focal laser
ablation[tiab] OR laser therap*[tiab] OR ILT[tiab] OR Intertitial laser
thermotherapy[tiab]) AND (magnetic resonance imaging [tiab] OR mpMRI[tiab] OR
multiparametric MRI[tiab] OR multiparametric magnetic resonance imaging [tiab])
AND (focal therapy[tiab] OR focal[tiab] OR focal treatment[tiab] OR localized
treatment[tiab] OR ablation[tiab] OR ablative therapy[tiab])
Results: 20
Results: 10
Results: 10
Automatic filtering
Time period: 2006 – 2016
Subjects: Humans
Language: English
Text availability: Full-text
After screening full-texts
Fig. 1  Overview of systematic research
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percent (29/37) works in an academic hospital, 14% (5/37) 
in private practice, and 8% (3/37) in a major urban hospital. 
Eighty-six percent (32/37) reported PCa as their main field 
of expertise and 73% (27/37) treat more than 150 patients 
per year. One participant (3%) reported not to have treated 
any patients. Online Resource 2 contains the participants. 
Figure 2 shows the main results.
Focal therapy
Clinically significant PCa (csPCa) is defined as any volume 
GS ≥ 3+4 (77%) and the lesion with both the largest volume 
and highest GS is considered the main index lesion (88%). 
Focal therapy for de novo PCa is defined as treatment of 
csPCa while leaving insignificant lesions under AS (88%). 
Subsequently, the same definition was used for FT as salvage 
treatment (80%). It is recommended to use FT as primary 
treatment of PCa in well-selected patients as alternative to 
RP or RT (81%). Focal laser ablation is optimal for targeting 
a specific focus (95%), rather than quadrant ablation (41%), 
hemi-gland ablation (24%) or subtotal ablation of the pros-
tate (14%) (Fig. 3). Both, in-bore transperineal (100%) or in-
bore transrectal (75%) approach are recommended for FLA. 
There was no consensus on the MRI–TRUS fusion approach. 
Preservation of EF (97%) and external urethral sphincter 
function (97%) are important reasons for choosing FLA over 
radical treatment. However, FLA is not appropriate for any 
patient outside of clinical trials (73%).
Eligibility
Eligibility for FLA is determined by GS (95%), volume 
(81%), location (77%), and the number of MRI-visible 
and biopsy-confirmed cancers (77%). Lower urinary tract 
symptoms are not a contraindication for FLA (89%). The 
maximum prostate volume is not a primary determinant 
of eligibility for FLA (100%). There was no consensus on 
patient selection and recommended PSA cut-off value rea-
sonable for FLA. Subsequently, panelists were of the opinion 
that PSA levels should not be considered or used for inclu-
sion (54%). The maximum volume of cancer foci suitable for 
FLA should be based on MRI (81%), however, it is recom-
mended not to exceed a tumor volume of 10–15 mL (76%). 
The panel recommended FLA in patients with low- and 
Fig. 2  Summary of the results
Fig. 3  Axial schematic views of prostate gland with cancer foci (in 
red) and ablation zones (in orange); a targeted ablation, b quadrant 
ablation, c hemi-gland ablation, and d subtotal ablation
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intermediate-risk (100%) or in patients with MRI-visible 
local recurrence (84%). It is also an acceptable strategy in 
patients with de novo PCa and GS ≤ 4+3 (72%). There was 
no consensus on the maximum GS in patients that require 
salvage therapy. However, salvage patients with only organ-
confined disease are suitable candidates for FLA (81%). 
Patients who are AS candidate (GS 3+3) and otherwise do 
not require treatment are not eligible for FLA (73%). Life 
expectancy is not a primary determinant of suitability for 
FLA (92%). However, FLA should be offered when the life 
expectancy is less than 10 years, but only when treatment 
may delay local progression (96%). It should be applied to 
patients whose life expectancy, excluding the PCa diagno-
sis, is greater than their expected disease-specific mortality 
(88%).
Biopsy and imaging
Histological confirmation is still required prior to FLA in 
the presence of a suspicious lesion (PI-RADS 4 or 5) on 
mpMRI (100%). Systematic biopsies remain necessary, even 
if an mpMRI suspicious lesion has already been sampled 
adequately by targeted biopsy (76%). However, 12-core 
biopsy alone is insufficient for patient selection for FLA 
(73%). The standard imaging tool for FT should be mpMRI 
(95%) and MRI–TRUS software fusion biopsy (86%) or in-
bore MRI-guided biopsy (86%) are recommended to assess 
suspicious lesions. Cognitive-targeted biopsy was defined as 
not adequate to evaluate a lesion on mpMRI (88%).
Outcome
According to the protocol, the prostate is regularly assessed 
by mpMRI and (systematic) biopsies after FLA. Treatment 
success is defined by a residual GS 3+3 obtained by random 
biopsy of the treatment area in combination with a negative 
mpMRI (95%). Residual in-field GS ≥ 3+4 on TRUS-guided 
biopsy is defined as treatment failure (84%), even with nega-
tive mpMRI (100%). Subsequently, a GS 4+3 based on in-
field TRUS-guided biopsy a negative mpMRI is also con-
sidered as treatment failure (97%).
Discussion
Consensus projects are valuable tools in fields where clini-
cal evidence is still developing. The provided statements 
and recommendations can contribute to standardization of a 
therapy for clinical utilization. The results of our consensus 
project reflect the opinion of 37 experts with experience in 
the field of FT for localized PCa. Image-guided FLA can be 
offered to carefully selected patients as alternative to radical 
treatment. It is most favorable for targeting a specific focus 
in patients with GS ≤ 4+3 and MRI-visible, biopsy-proven 
PCa. Statements provided by this consensus project can be 
used as guidelines and recommendations for community-
based (interventional) radiologists and urologists performing 
or referring patients for FLA.
Several other consensus projects have been conducted to 
provide the opinion of experts in the field. Postema et al. 
defined FT as targeting all identified tumors and with the 
aim to eradicate all csPCa (GS ≥ 3+4) [17]. Donaldson et al. 
described FT as focal ablation of the main index or dominant 
lesion and recommended FT for both targeted and quad-
rant ablations. They did not agree on the maximum tumor 
volume suitable for FT [18]. Our panel assigned similar 
definitions to both treatments of de novo PCa and salvage 
therapy. Commonly, the largest lesion is simultaneously the 
highest GS and consequently the main index lesion [19]. 
Our experts considered the lesion with both the largest vol-
ume and highest GS as the main index lesion and agreed 
on targeted ablation of a specific focus rather than quadrant 
ablation with a maximum tumor volume of 10–15 mL on 
mpMRI. Considering the MRI-invisible portion of a tumor is 
likely to extend significantly as the tumor volume increases, 
ablation of a tumor of this size requires significant margins. 
There has been a shift in eligibility criteria in recent years 
from low- to intermediate-risk due to growing confidence in 
AS for low-risk cancers [20–22].
Currently, a wide variety of energy sources are available 
for FT. This project focused on one technique, being image-
guided FLA. Transrectal FLA is performed under local anes-
thesia and can, therefore, be offered as outpatient procedure. 
It only takes a few minutes to create a sharp ablation zone 
which results in relatively short procedure times and quick 
patient recovery [11]. Furthermore, multiple ablations can 
be performed during one session and repeated treatments, 
i.e., FLA or secondary whole-gland therapy are still viable 
options after FLA. Number of studies concluded FLA as fea-
sible and safe while preserving urinary and sexual function 
[7, 12, 15]. Despite the promising results, efficacy and onco-
logical outcomes are not well established. Image-guided 
FLA is limited to centers with experienced (interventional) 
radiologists or urologists and the use is still sporadic due to 
high costs and lack of insurance coverage. Moreover, the 
FLA procedure is less optimal for large-sized PCa com-
pared to other modalities. Appropriate patient selection and 
assessing the efficacy of MRI-guided interventions remain 
a controversy. Other studies agreed on oncologic efficacy 
similar to our panel and stated that insignificant cancers in 
post-treatment biopsies do not need further treatment [18, 
24]. Our experts agreed on in-bore MRI-guided biopsy 
being adequate for assessing a suspicious lesion on mpMRI 
or post-treatment biopsies similar to other studies [25, 26]. 
Cognitive-targeted biopsy was defined as not adequate. 
Remarkably, Yaxley et al. showed no significant difference 
2151World Journal of Urology (2019) 37:2147–2153 
1 3
between in-bore MRI-guided biopsy or cognitive-targeted 
biopsy and described the importance of identifying the 
lesion on mpMRI [23].
Number of uncertainties were identified and remain top-
ics for further research. The role of FLA as salvage therapy 
was discussed during a face-to-face meeting [27]. Valerio 
et al. reported five series (n = 115) with follow-up ranging 
between 3 and 90 months, receiving FT (i.e., cryosurgery, 
HIFU, and MRI-guided brachytherapy) after RT failure and 
described the pad-free continence (87–100%), intact EF 
(29–40%), and the absence of csPCa in 92% [7]. Second, 
the use of both PSA and PSA-density (PSAD) as eligibility 
criteria for FLA remained undefined. Other studies consid-
ered a PSA ≤ 15 ng/mL eligible for FT and demonstrated 
PSAD as the most accurate predictor of PCa aggressiveness. 
The PSA was only used to predict seminal vesicle invasion 
[28, 29]. Third, there was no consensus on the MRI–TRUS 
fusion approach for FLA as experience has been limited to 
date. Natarajan et al. allowed accurate ablation of the lesion 
with MRI–TRUS fusion (n = 11). However, in-field biopsy 
after 6 months showed a GS 3+3 (n = 3) or csPCa (n = 4) [9].
Our study has several limitations. First, while using 
the Delphi method the results are based on the opinion of 
selected individuals and does not represent the PCa commu-
nity at large. Expert selection can cause selection bias based 
on personal enthusiasm and preferences, since non-believers 
likely did not agree to participate. Also, all four question-
naires were not completed by every participating expert and 
the overall response rates were 65–100%.
Conclusion
Focal laser ablation is a promising outpatient technique 
for treatment of clinically localized PCa in patients with 
GS ≤ 4+3 and MRI-visible, biopsy-proven cancer. This 
study has shown that despite the large number of low- and 
intermediate-risk disease, patient selection and eligibil-
ity criteria for FLA need to be evaluated based on which 
patients will benefit the most before clinical implementation 
is justified.
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